Vanguard Group’s La Jolla Pharmaceutical Company LJPC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-825,481
| Closed | -$2.63M | – | 4671 |
|
|
2022
Q2 | $2.63M | Hold |
825,481
| – | – | ﹤0.01% | 3689 |
|
|
2022
Q1 | $3.52M | Sell |
825,481
-3,962
| -0.5% | -$17.3K | ﹤0.01% | 3696 |
|
|
2021
Q4 | $3.86M | Sell |
829,443
-60,459
| -7% | -$252K | ﹤0.01% | 3755 |
|
|
2021
Q3 | $3.55M | Buy |
889,902
+5,677
| +0.6% | +$22.5K | ﹤0.01% | 3840 |
|
|
2021
Q2 | $3.79M | Sell |
884,225
-94,629
| -10% | -$405K | ﹤0.01% | 3734 |
|
|
2021
Q1 | $4.15M | Sell |
978,854
-69,567
| -7% | -$383K | ﹤0.01% | 3624 |
|
|
2020
Q4 | $4.07M | Sell |
1,048,421
-17,760
| -2% | -$75.9K | ﹤0.01% | 3448 |
|
|
2020
Q3 | $4.3M | Buy |
1,066,181
+53,877
| +5% | +$223K | ﹤0.01% | 3228 |
|
|
2020
Q2 | $4.31M | Sell |
1,012,304
-3,582
| -0.4% | -$21.8K | ﹤0.01% | 3164 |
|
|
2020
Q1 | $4.27M | Sell |
1,015,886
-11,458
| -1% | -$72.4K | ﹤0.01% | 3037 |
|
|
2019
Q4 | $4.04M | Sell |
1,027,344
-1,437
| -0.1% | -$8.49K | ﹤0.01% | 3238 |
|
|
2019
Q3 | $9.05M | Sell |
1,028,781
-16,511
| -2% | -$156K | ﹤0.01% | 2866 |
|
|
2019
Q2 | $9.67M | Buy |
1,045,292
+12,097
| +1% | +$91.2K | ﹤0.01% | 2878 |
|
|
2019
Q1 | $6.64M | Buy |
1,033,195
+418,173
| +68% | +$2.72M | ﹤0.01% | 3023 |
|
|
2018
Q4 | $5.8M | Sell |
615,022
-365,314
| -37% | -$5.5M | ﹤0.01% | 3020 |
|
|
2018
Q3 | $19.7M | Buy |
980,336
+11,083
| +1% | +$290K | ﹤0.01% | 2582 |
|
|
2018
Q2 | $28.3M | Buy |
969,253
+41,384
| +4% | +$1.28M | ﹤0.01% | 2409 |
|
|
2018
Q1 | $27.6M | Buy |
927,869
+125,857
| +16% | +$4.06M | ﹤0.01% | 2365 |
|
|
2017
Q4 | $25.8M | Buy |
802,012
+5,948
| +0.7% | +$194K | ﹤0.01% | 2383 |
|
|
2017
Q3 | $27.7M | Sell |
796,064
-20,715
| -3% | -$666K | ﹤0.01% | 2338 |
|
|
2017
Q2 | $24.3M | Buy |
816,779
+154,494
| +23% | +$4.43M | ﹤0.01% | 2375 |
|
|
2017
Q1 | $19.8M | Buy |
662,285
+138,155
| +26% | +$3.53M | ﹤0.01% | 2448 |
|
|
2016
Q4 | $9.19M | Buy |
524,130
+18,426
| +4% | +$353K | ﹤0.01% | 2788 |
|
|
2016
Q3 | $12M | Buy |
505,704
+21,642
| +4% | +$408K | ﹤0.01% | 2596 |
|
|
2016
Q2 | $7.75M | Buy |
484,062
+8,687
| +2% | +$156K | ﹤0.01% | 2770 |
|
|
2016
Q1 | $9.94M | Buy |
475,375
+18,691
| +4% | +$333K | ﹤0.01% | 2619 |
|
|
2015
Q4 | $12.3M | Buy |
456,684
+24,482
| +6% | +$668K | ﹤0.01% | 2522 |
|
|
2015
Q3 | $12M | Buy |
432,202
+54,035
| +14% | +$1.7M | ﹤0.01% | 2509 |
|
|
2015
Q2 | $9.27M | Buy |
378,167
+27,897
| +8% | +$575K | ﹤0.01% | 2717 |
|
|
2015
Q1 | $6.41M | Buy |
350,270
+23,026
| +7% | +$467K | ﹤0.01% | 2864 |
|
|
2014
Q4 | $6.04M | Buy |
327,244
+9,500
| +3% | +$113K | ﹤0.01% | 2795 |
|
|
2014
Q3 | $3.05M | Buy |
+317,744
| New | +$3.16M | ﹤0.01% | 3090 |
|
Vanguard Group's LJPC Position: Q3 2022 in Review
Vanguard Group sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2022, closing a stake of 825,481 shares — an estimated $2.63M sold.
Vanguard Group first reported a position in LJPC in Q3 2014 and held it in 32 quarters. The position peaked at $28.3M in Q2 2018. 0 funds tracked by Wall St. Rank hold LJPC as of Q3 2022.
- Vanguard Group reported no remaining La Jolla Pharmaceutical Company position as of Q3 2022 after selling out during the quarter.
- Vanguard Group sold 825,481 La Jolla Pharmaceutical Company shares in Q3 2022, an estimated $2.63M.
- Vanguard Group first reported a position in La Jolla Pharmaceutical Company in Q3 2014 and held it in 32 quarters.
- Vanguard Group's La Jolla Pharmaceutical Company position peaked at $28.3M in Q2 2018.
- 0 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2022.
Based on Vanguard Group's 13F filing for Q3 2022, filed 14 Nov 2022.